Pages that link to "Q5387640"
Jump to navigation
Jump to search
The following pages link to Eric J. Topol (Q5387640):
Displaying 50 items.
- Enrichment of sequencing targets from the human genome by solution hybridization (Q21183896) (← links)
- Development of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patients (Q21202033) (← links)
- Assessing the impact of population stratification on genetic association studies (Q22337235) (← links)
- Eric Topol: The wireless future of medicine (Q22976994) (← links)
- Gain-of-function ADCY5 mutations in familial dyskinesia with facial myokymia (Q24293635) (← links)
- Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease (Q24312938) (← links)
- Mechanism and effect of thrombospondin-4 polymorphisms on neutrophil function (Q24314830) (← links)
- Thrombospondin-4 and its variants: expression and differential effects on endothelial cells (Q24319267) (← links)
- Identification of four gene variants associated with myocardial infarction (Q24536320) (← links)
- Fluid phase biopsy for detection and characterization of circulating endothelial cells in myocardial infarction (Q24564065) (← links)
- Mutation of MEF2A in an inherited disorder with features of coronary artery disease (Q24669679) (← links)
- Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors (Q24796005) (← links)
- Debate: PCI or CABG for multivessel disease? Viewpoint: No clear winner in an unfair fight (Q24799198) (← links)
- Systematic adjudication of myocardial infarction end-points in an international clinical trial (Q24805625) (← links)
- Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study (Q24805692) (← links)
- Towards precise classification of cancers based on robust gene functional expression profiles (Q24811476) (← links)
- Novel wireless devices for cardiac monitoring (Q26828642) (← links)
- Annotating individual human genomes (Q26999723) (← links)
- Cystic fibrosis in an era of genomically guided therapy (Q27003971) (← links)
- Stop the privatization of health data (Q27132103) (← links)
- A laboratory in your pocket (Q27276923) (← links)
- Prediction of Causal Candidate Genes in Coronary Artery Disease Loci (Q27342192) (← links)
- Moving From Digitalization to Digitization in Cardiovascular Care: Why Is it Important, and What Could it Mean for Patients and Providers? (Q28084558) (← links)
- Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET) (Q28165540) (← links)
- Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study (Q28165755) (← links)
- International variation in the use of evidence-based medicines for acute coronary syndromes (Q28166289) (← links)
- Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices (Q28166576) (← links)
- Oral glycoprotein IIb/IIIa inhibitors: why don't they work? (Q28166805) (← links)
- Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events (Q28166894) (← links)
- Adjunctive therapy for percutaneous revascularization in acute myocardial infarction (Q28167253) (← links)
- Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes (Q28167317) (← links)
- Aspirin dose and six-month outcome after an acute coronary syndrome (Q28167843) (← links)
- Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins (Q28168105) (← links)
- Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial) (Q28168414) (← links)
- Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial (Q28170627) (← links)
- Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials (Q28174968) (← links)
- Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery (Q28175229) (← links)
- Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials (Q28176219) (← links)
- Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial (Q28176922) (← links)
- Integrin alphaIIbbeta3 and its antagonism (Q28183152) (← links)
- Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial (Q28185728) (← links)
- Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention (Q28186016) (← links)
- Profile and prevalence of aspirin resistance in patients with cardiovascular disease (Q28186905) (← links)
- Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein (Q28189164) (← links)
- (Q28190437) (← links)
- Common variations in platelet glycoproteins: pharmacogenomic implications (Q28191774) (← links)
- Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting (Q28191825) (← links)
- Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting (Q28191931) (← links)
- Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial (Q28192274) (← links)
- Prognostic significance of elevated troponin I after percutaneous coronary intervention (Q28193100) (← links)